Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Cash & Current Investments: 2016-2025

Historic Cash & Current Investments for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Sep 2025 value amounting to $369.6 million.

  • Rocket Pharmaceuticals' Cash & Current Investments fell 8.91% to $369.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 billion, marking a year-over-year decrease of 4.40%. This contributed to the annual value of $372.3 million for FY2024, which is 0.22% down from last year.
  • Per Rocket Pharmaceuticals' latest filing, its Cash & Current Investments stood at $369.6 million for Q3 2025, which was down 27.55% from $510.2 million recorded in Q2 2025.
  • Rocket Pharmaceuticals' 5-year Cash & Current Investments high stood at $680.2 million for Q1 2021, and its period low was $356.4 million during Q4 2022.
  • Over the past 3 years, Rocket Pharmaceuticals' median Cash & Current Investments value was $519.0 million (recorded in 2024), while the average stood at $509.7 million.
  • As far as peak fluctuations go, Rocket Pharmaceuticals' Cash & Current Investments spiked by 88.28% in 2021, and later plummeted by 37.45% in 2024.
  • Rocket Pharmaceuticals' Cash & Current Investments (Quarterly) stood at $388.7 million in 2021, then fell by 8.32% to $356.4 million in 2022, then rose by 4.71% to $373.2 million in 2023, then fell by 0.22% to $372.3 million in 2024, then dropped by 8.91% to $369.6 million in 2025.
  • Its Cash & Current Investments was $369.6 million in Q3 2025, compared to $510.2 million in Q2 2025 and $586.6 million in Q1 2025.